Cargando…
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
The endocrine and therapeutic effects of the aromatase inhibitor fadrozole hydrochloride have been assessed in 80 post-menopausal patients with recurrent breast cancer after tamoxifen failure. Treatment allocation was randomly 0.5, 1.0 or 2.0 mg orally b.d. Eight patients were not assessable for res...
Autores principales: | Bonnefoi, H. R., Smith, I. E., Dowsett, M., Trunet, P. F., Houston, S. J., da Luz, R. J., Rubens, R. D., Coombes, R. C., Powles, T. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074462/ https://www.ncbi.nlm.nih.gov/pubmed/8595171 |
Ejemplares similares
-
Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.
por: Gunson, D. E., et al.
Publicado: (1995) -
Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: Lønning, P. E., et al.
Publicado: (1989) -
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
por: Shearer, R. J., et al.
Publicado: (1990) -
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992) -
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1991)